748 results about "Staphylococcus cohnii" patented technology

A method and apparatus for preventing and treating septicemia in patient blood. The extracorporeal system includes an anti-microbial device to kill at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 90% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms as well as the patient's cells and include endotoxins from gram negative bacteria, exotoxins from gram negative and gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, complement proteins C3a and C5a, and brandykinin.

The invention provides an Enterococcus faecium ANSE228 of which the collection number is CGMCC No.4082. The invention also provides application of the Enterococcus faecium ANSE228 to inhibition of salmonella pullorum and/or Escherichia coli and/or Staphylococcus aureus. The Enterococcus faecium ANSE228 is obtained by processes of repeated separation, purification, rejuvenation and the like, and has high biological activity, obvious probiotic property, high adversity resistance and the like. The invention also provides a microecological agent which contains the Enterococcus faecium ANSE228. When the microecological agent is added into drinking water and/or feeds for breeding animals, the Enterococcus faecium ANSE228 can be quickly activated and reproduced and a dominant beneficial flora can be formed after the Enterococcus faecium ANSE228 is fed into intestinal canals of the animals, and the Enterococcus faecium ANSE228 has the effects of reducing a harmful flora in the intestinal canals, adjusting microecological balance of the intestinal canals, substituting for medicaments such as antibiotic and the like, and improving weight increment of the animals and the utilization rate of the feeds.

The invention discloses a salt-tolerant microbial agent and a preparation method thereof. The microbial agent contains staphylococcus cohnii FSND-C, arthrobacter creatinolyticus FDN-1, flavobacterium mizutaii FDN-2, paracoccus denitrificans DN-3 and methylobacterium phyllosphaerae SDN-3. The microbial agent can achieve removal of ammonia nitrogen, total nitrogen and CODcr in the same reactor, has a good wastewater treatment effect, and can achieve short-cut nitrification and denitrification or simultaneous nitrification and denitrification while removing COD. Staphylococcus cohnii FSND-C can utilize various carbon sources, has certain salt tolerance, can be applied to the high-salinity wastewater treatment process, simultaneously can secrete a substance under environmental stimulus to enhance the flocculability of sludge, and further widens the application range of the microbial agent.

Disclosed are antibodies that block the binding of fibronectin protein to fibronectin. Also disclosed are site specifically-mutated and truncated peptide epitopes derived from the fnbA and fnbB genes of Staphylococcus aureus, the fnba and fnbB genes of Streptococcus dysgalactiae, and the sfb gene of Streptococcus pyogenes, and nucleic acid segments encoding these peptides and epitopes. The anti-(fibronectin binding site) antibodies, peptides and epitopes that give rise to antibodies that block the binding of fibronectin binding proteins to fibronectin, and DNA segments encoding these proteins and are of use in various screening, diagnostic and therapeutic applications including active and passive immunization and methods for the prevention of streptococcal and staphylococcal colonization in animals or humans. These. DNA segments and the peptides derived therefrom are proposed to be of use directly in the preparation of vaccines and also for use as carrier proteins in vaccine formulations.

The present invention encompasses a novel S. aureus bioconjugate vaccine. More generally, the invention is directed to Gram-positive and other bioconjugate vaccines containing a protein carrier, at least one polysaccharide such as a capsular Gram-positive polysaccharide, and, optionally, an adjuvant or pharmaceutically acceptable carrier. The instant invention also includes methods of producing Gram-positive and other bioconjugate vaccines. An N-glycosylated protein is also provided that contains one or more polysaccharides such as Gram-positive polysaccharides. The invention is additionally directed to engineered prokaryotic organisms comprising nucleotide sequences encoding a glycosyltransferase of a first prokaryotic organism and a glycosyltransferase of a second prokaryotic organism. The invention further includes plasmids and prokaryotic cells transformed with plasmids encoding polysaccharides and enzymes which produce an N-glycosylated protein and/or bioconjugate vaccine. Further, the invention is directed to methods of inducing an immune response in a mammal comprising administering said bioconjugate vaccines.

The invention relates to a biological denitrification method for salt-containing sewage, which comprises the following steps: adding a denitrification microbial inoculant into a biochemical sewage treatment system, and simultaneously starting the nitrification-denitrification biological denitrification treatment processes, wherein the sewage treatment temperature is 18-40 DEG C, the dissolved oxygen is 0.1-5 mg/L, and the pH value is 7.0-9.0. The denitrification microbial inoculant contains one or two of Staphylococcuscohnii FSDN-C, Arthrobactercreatinolyticus FDN-1 and Flavobacteriummizutaii FDN-2, and also contains one or two of Paracoccusdenitrificans DN-3 and Methylobacteriumphyllosphaerae SDN-3. The method provided by the invention can effectively treat high-salt-content sewage, enhances the adsorptivity and flocculence for sludge, has wide application range for wastewater quality and high impact resistance to salt-containing sewage, and obviously enhances the sewage treatment effect on the premise of removing pollutants, such as ammonia nitrogen, COD (chemical oxygen demand) and the like.

Vaccines comprising an S. aureus alpha-toxin antigen and a pharmaceutically acceptable carrier are provided, and are useful for treating and preventing infections. The S. aureus alpha-toxin antigen may contain at least two alterations that reduce its toxicity and/or may be conjugated to or co-administered with another bacterial antigen. The vaccines may comprise one or more other bacterial antigens. Antibody compositions comprising antibodies to alpha-toxin and optionally one or more other bacterial antigens also are provided, and are useful for treating and preventing infections.

The invention relates to the detection field of microorganism foodborne pathogens and discloses a method for rapidly detecting and screening staphylococcus aureus, which adopts bio-functionalized superparamagnetic nano particles and immunized quantum dots to immunologically recognize target microorganisms to realize to specificity detection on the foodborne pathogens (staphylococcus aureus). According to the method, target bacteria can be rapidly separated from various samples, and enrichment is also performed efficiently; and besides, bacteria separated by the enrichment can be marked rapidly by fluorescence, so that the bacteria can be qualitatively identified by a fluorescence microscope and can be quantitatively detected by a fluorescence photometer. The method is convenient and simple to operate, and has high reliability and a low requirement on corollary equipment.

The invention discloses a kit and method for staphylococcus aureus CRISPR locus detection. The kit comprises three pairs of specific primers designed according to three CRISPR locus gene sequences of staphylococcus aureus. The invention further discloses the method for staphylococcus aureus CRISPR locus detection. The three pairs of specific primers are utilized to amplify corresponding CRISPR fragments from sample genome DNAs. The kit and the detection method are simple to operate, high in sensitivity and specificity and low in detection cost and have good popularization and application values.

Prokayrotic FAB I polypeptides and DNA (RNA) encoding such FAB I and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such FAB I for the treatment of infection, such as bacterial infections. Antagonists against such FAB I and their use as a therapeutic to treat infections, such as staphylococcal infections are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence of FAB I nucleic acid sequences and the polypeptides in a host. Also disclosed are diagnostic assays for detecting polynucleotides encoding FAB I and for detecting the polypeptide in a host.

The invention relates to a novel veterinary antibacterial agent and in particular relates to a lauroyl arginine ethyl ester ion pair compound derivative which is prepared from lauroyl arginine ethyl ester LAE and an organic acid through reactions. As a livestock aquatic animal antibacterial agent, the derivative is capable of preventing and treating duckling riemerella anatipestifer diseases caused by riemerella anatipestifer, is capable of treating peritonitis diseases caused by escherichia coli and staphylococcus aureus, is capable of preventing and treating fish septicemia caused by aeromonas sobria, and has remarkably improved prevention and treatment effects when being compared with a conventional LAE veterinary antibacterial agent. The derivative can be completely degraded in human bodies and animal bodies and is small in toxic and side effect, environment drug resistance bacteria caused by residual antibacterial agents discharged into the environment can be avoided, and small adverse environment influence can be caused while an effective antibacterial effect is achieved.

Disclosed are methods of identifying a methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-sensitive Staphylococcus aureus (MSSA) in a sample. The present invention provides a diagnostic method comprising modification of sequences of S. aureus by converting non-methylated cytosine residues ultimately into thymidine residues in the target nucleic acid. The invention further provides for the detection of modified sequences derived from the spa gene, the mecA gene, and the integrated SCCmec cassette of S. aureus.

Methods of inhibiting S. aureus propagation, and screening for compounds that inhibit S. aureus propagation, are described. A method of inhibiting S. aureus propagation comprises either inhibiting or stabilizing ribosomal binding of a specific S. aureus tRNA in the S. aureus by an amount sufficient to inhibit S. aureus protein expression. A method of screening for compounds useful for inhibiting S. aureus propagation comprises contacting a specific S. aureus tRNA to a ribosome that binds that tRNA in the presence of the test compound and an mRNA that codes for methionine and arginine (i.e., includes the sequence AUGAGA), and then determining whether the compound inhibits the binding of that tRNA.

The invention features methods and compositions for treatment or prevention of infection by, or disease caused by infection with, Staphylococcus spp., particularly S. aureus.

The invention discloses a complex enrichment medium used for salmonella, listeria monocytogenes and staphylococcus aureus and a method for preparing the same. The complex enrichment medium comprises the following components in weight portion: 15 to 19 portions of tryptone, 2 to 4 portions of peptone, 2 to 3 portions of sodium dihydrogen phosphate, 2 to 3 portions of glucose, 0.5 to 1.5 portions of aesculin, 1, 000 portions of distilled water, 1 to 2.5 portions of sodium pyruvate, 3 to 10.0 portions of mannitol, 1.0 to 25.0 portions of sodium chloride, 1 to 2.5 portions of lithium chloride, 0.0001 to 0.0002 portion of potassium tellurite, and 0.005-0.015 portion of nalidixic acid, wherein the pH value is between 7.1 and 7.5. The complex enrichment medium can inhibit the growth of other pathogenic microorganisms while performing enrichment on three target pathogens, thus the complex enrichment medium can be directly applied to the isolation culture and the biological assay test of target bacteria, and can also be directly applied to a detection technology of a plurality of pathogens based on one detection platform for multiple PCR and the like to make a diagnostic report.

The invention relates to a kitchen garbage degrading composite microbial inoculum and a preparation method and application thereof. The kitchen garbage degrading composite microbial inoculum is prepared by mixing a mixed inoculum of bacillus amyloliquefaciens, radiation-resistant methylobacterium, dispersed pantoea, pseudomonas oryzihabitans, citrobacter freundii and staphylococcus cohnii and a carrier, wherein the mass of the mixed inoculum accounts for 15-25% of the total mass of the kitchen garbage-degrading composite microbial inoculum; the mass ratio of the bacillus amyloliquefaciens, the radiation-resistant methylobacterium, the dispersed pantoea, the pseudomonas oryzihabitans, the citrobacter freundii and the staphylococcus cohnii is (1.5-3):(1-1.5):(1-1.5): (1-1.5):(1-1.5):(1-1.5); the kitchen garbage-degrading composite microbial inoculum is used for degrading kitchen garbage. Compared with the prior art, the kitchen garbage degrading composite microbial inoculum has the advantages as follows: the kitchen garbage degrading composite microbial inoculum can effectively degrade common vegetables, grains, fish, poultry meat and other kitchen garbage, has the degradation rate being above 80%, is high in degradation speed rate and small in odor, does not produce pollutants or poisonous substances, and is low in cost and stable in performance.

The present invention relates to a novel bacteriophage, more precisely a Podoviridae bacteriophage having killing activity specific to Staphylococcus aureus which is the causing agent of infectious disease in human and animals, a pharmaceutical composition for the prevention and treatment of the disease caused by Staphylococcus aureus, an antibiotic and a disinfectant containing the bacteriophage as an active ingredient.

The present invention discloses one plant lactobacillus strain and its application. The plant lactobacillus, Lactobacillus plantarum L323 CGMCC No. 1329, is separated from Chinese pregnant woman's vaginal secretion, and has relatively high bacteriotasis on common vaginal pathogens, such as staphylococcus aureus, candida albicans, colibacillus and vaginal Gardnar bacillus, and acid producing and H2O2 producing capacity higher than other lactobacillus. The plant lactobacillus, Lactobacillus plantarum L323 CGMCC No. 1329, may be used in preparing vaginal microbial preparation for preventing and/or treating vaginal infectious diseases.

The invention discloses a submerged fermentation phellinus linteus mycelium glycoprotein, a usage and a separation extraction preparation method thereof, the complex is the complex of heteropolysaccharide and protein, wherein, the content of the heteropolysaccharide is 15 to 20 percent, and the heteropolysaccharide is composed of three monosaccharides of glucose monosaccharide, xylose and mannose; the content of the protein is 80 to 85 percent, and the protein is composed of 18 amino acids of aspartic acid, glutamic acid, arginine and so on; and the weight-average molecular weight is 20 to 40KD. The glycoprotein complex uses bran extract liquid as a main ingredient for preparing a culture medium, the phellinus linteus mycelium is produced by the submerged fermentation of the phellinus linteus bacterial strain liquid, the homogenization, the cold-water extraction, the centrifugalization, the collection of supernatant liquid, the precipitation of ammonium sulfate, the dialysis and the DEAE-Sepharose Fast Flow column chromatography are carried out for system separating and purifying the glycoprotein complex. The anti-bacterial glycoprotein is used for preparing the anti-bacterial dugs which have inhibitory effects on escherichia coil and staphylococcus aureus. At the same time, the glycoprotein complex can be used for the separation and the purification of the glycoprotein from the mycelium obtained by the submerged fermentation of various medical and edible fungi.

The present invention relates to antimicrobial deoxyribonuclease-based compositions that inhibit growth and proliferation of Staphylococcus aureus bacteria. The present invention also relates to methods of administering the compositions in the treatment and prevention of S. aureus infections. The present invention also relates to methods of administering the compositions in the eradication of S. aureus nasal carriage, in order to prevent the transmission of S. aureus bacteria

The invention relates to the field of microorganism detection, in particular to a staphylococcus aureus methicillin resistant strain PCR (Polymerase Chain Reaction) detection kit. The invention has the technical scheme of amplifying and detecting a highly conservative specific nucleic acid sequence nuc gene in the staphylococcus aureus gene by using the polymerase chain reaction and molecular beacon and fluorescent probe technologies and simultaneously amplifying and detecting the drug resistant nucleic acid sequence mecA gene to judge whether the strain is a methicillin resistant strain of staphylococcus aureus. The invention also provides PCR amplification primers of the nuc gene and the mecA gene and the sequence of the probe. The kit is applicable to the rapid detection of the staphylococcus aureus methicillin resistant strain in a clinical specimen of a suspect staphylococcus aureus infector and has the advantages of high sensitivity, high specificity, stability, timeliness, convenience for operation and the like.